Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
about
Methylenedioxymethamphetamine ('Ecstasy')-induced immunosuppression: a cause for concern?Real-World Effectiveness and Safety of a Live-Attenuated Herpes Zoster Vaccine: A Comprehensive ReviewLong-term safety and efficacy of infliximab for the treatment of ankylosing spondylitisVaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalitiesNovel approaches and challenges to treatment of central nervous system viral infectionsNew insights into the impact of neuro-inflammation in rheumatoid arthritisUpdated consensus statement on the use of rituximab in patients with rheumatoid arthritis.What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Synaptic Plasticity and Neurological Disorders in Neurotropic Viral InfectionsAnti-tumor necrosis factor therapy and influenza: keeping it in perspective.Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data.Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry.Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.Antibody to varicella-zoster virus immediate-early protein 62 augments allodynia in zoster via brain-derived neurotrophic factor.Herpes Zoster and Recurrent Herpes ZosterRisk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.Neurological disorders and inflammatory bowel diseasesLocal and systemic cytokine expression in patients with postherpetic neuralgia.Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments.Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study.Clinical use of anti-TNF therapy and increased risk of infections2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis.Risk of infections associated with biological treatment in inflammatory bowel disease.Differences between post-authorization adverse drug reactions of biopharmaceuticals and small molecules.Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximabHerpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis.Sustainability of rituximab therapy in different treatment strategies: results of a 3-year followup of a German biologics registerHerpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case-control study.Tumor necrosis factor inhibitors - state of knowledge.The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with speciaTumor necrosis factor blockade and the risk of viral infectionRisk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
P2860
Q24627529-91844EAD-93FA-4173-A8A7-681EF258ACECQ26748712-1BAEA294-5D99-4ECC-A025-49B41265BE56Q26774173-0EC5AD20-FC5D-49B2-828C-525F64C56B0AQ26796420-ED5DA8BC-A5F9-4BD5-A4A2-9280040E832EQ26862449-6402B576-6022-4771-96AA-76718B51AC04Q27023946-B7DD9082-9F13-45B0-9B5B-54BC769F5715Q27691388-307FF9ED-7079-4B07-9533-E4A7A9800324Q28074148-E14B0039-B486-4F32-AEDA-DEB2470A37FDQ28088477-3D42645F-09F0-4CDB-A48E-7EBA10D8116DQ30397819-A4D62A41-183B-4296-AE8F-BFFFF5D54C91Q30574065-175715A7-ECBD-45E2-8E56-07A9F7C0D63BQ30717002-818D06BA-9FFC-45CE-9D54-C7B19DECBA90Q30725001-74670667-FD89-49B9-921C-8E07369B80ACQ31158500-1B859AA6-4510-47E7-874F-54E2AB512DE7Q33614430-7DC1B87C-1C2A-41B0-80B8-289F7DEF7128Q33629526-3ECA9271-987A-4D10-9CF0-E6F3941EFD27Q33873620-4F7976F5-4EE8-4F4A-BEAD-81EC679960C1Q33958822-DC6B103E-F6B2-4B7C-ACEF-8A0F9840088FQ34051040-5EEE021D-CF40-4452-83AE-AE7B992AD957Q34152994-C0361C9F-0790-4905-8E5D-9A4B755267E9Q34308422-A0E740BF-60A3-4885-97E9-37611D0A0199Q34338096-3BBC7EAA-D466-4CE1-A73F-8FF7D82F73CAQ34390072-EFC8CE9D-C040-494A-848B-36B1D691F3E8Q34548430-429DDE13-C6C4-47AB-BD4A-C7B1778C7858Q34552028-2DF241FC-F611-4FC2-A5BB-D4E129AB2D2AQ34582779-A3D9966C-010A-41D4-94E2-63AE3C71B492Q34658023-E4C302E7-2840-4028-8B5A-DCEEC5AA9327Q34667717-C016E912-B30E-4581-9864-0870F1A0D18DQ34672043-690DFE5D-B627-4EAD-85F1-720B96F9ABD0Q34803197-5F8284D8-9190-499E-8F78-CAF295A0F587Q34851473-3ECBFBB3-2BCE-4E5E-A450-3B5A4B5BC745Q34905686-D0626BB2-2E55-46A2-A02B-BE79244BC7D1Q34974335-E93BD295-25A8-42CA-9C89-3BF7DA3257A2Q34984568-D7063791-F3CD-4B81-8ABC-9E25CF27453EQ34986307-7FD49AA5-3609-42CE-BF29-B0D214FD7363Q35018415-5D0CCE28-E139-4EBD-952F-095E68238E7BQ35161630-57DCDE61-96C1-4121-93A9-7476A64E736AQ35200349-0535B1E5-40CB-445F-8F58-0BB4529AE121Q35237588-887B8384-8216-4B0F-A365-58A9FF0121B2Q35249608-A70B4E4C-4EED-46AB-B218-490800E748D5
P2860
Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Risk of Herpes Zoster in Patie ...... Treated With Anti–TNF-α Agents
@ast
Risk of Herpes Zoster in Patie ...... Treated With Anti–TNF-α Agents
@en
Risk of Herpes Zoster in Patie ...... Treated With Anti–TNF-α Agents
@nl
type
label
Risk of Herpes Zoster in Patie ...... Treated With Anti–TNF-α Agents
@ast
Risk of Herpes Zoster in Patie ...... Treated With Anti–TNF-α Agents
@en
Risk of Herpes Zoster in Patie ...... Treated With Anti–TNF-α Agents
@nl
prefLabel
Risk of Herpes Zoster in Patie ...... Treated With Anti–TNF-α Agents
@ast
Risk of Herpes Zoster in Patie ...... Treated With Anti–TNF-α Agents
@en
Risk of Herpes Zoster in Patie ...... Treated With Anti–TNF-α Agents
@nl
P921
P3181
P356
P1476
Risk of Herpes Zoster in Patie ...... Treated With Anti–TNF-α Agents
@en
P2093
Anja Strangfeld
P3181
P356
10.1001/JAMA.2009.146
P407
P577
2009-02-18T00:00:00Z